Substance P analogs containing α,α-dialkylated amino acids with potent anticancer activity

Journal of Peptide Science

Volumn 13, Issue 8, 2007, Pages 544-548

  Prasad, Sudhanand ^a   Mathur, Archna ^a   Jaggi, Manu ^a   Singh, Anu T ^a   Mukherjee, Rama ^a  

^a DABUR RESEARCH FOUNDATION   (India)

Author keywords

, dialkylated amino acids; Anticancer peptides; Substance P

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BUTANOYL DEXTRO ARGINYLPROLYLLYSYLPROLYL DEXTRO PHENYLALANYLGLUTAMINYL DEXTRO TRYPTOPHYLPHENYLALANYL DEXTRO TRYPTOPHYLLEUCYL 11 CYCLOLEUCYLAMIDE; DEXTRO 5 PHENYLALANYL 6 GLUTAMINYL DEXTRO 7 TRYPTOPHYL 8 PHENYLALANYL DEXTRO 9 TRYPTOPHYL 10 LEUCYL 11 CYCLOLEUCYLAMIDE; DEXTRO ARGINYLPROLYLLYSYLPROLYL 5 ALPHA ISOBUTYRIC ACID GLUTAMINYL DEXTRO TRYPTOPHYLPHENYLALANYL DEXTRO TRYPTOPHYL 10 ALPHA ISOBUTYRIC ACID LEUCYLAMIDE; DEXTRO ARGINYLPROLYLLYSYLPROLYL DEXTRO PHENYLALANYLGLUTAMINYL DEXTRO TRYPTOPHYLPHENYLALANYL DEXTRO TRYPTOPHYLLEUCYL 11 ALPHA AMINO ISOBUTYRIC ACID AMIDE; DEXTRO ARGINYLPROLYLLYSYLPROLYL DEXTRO PHENYLALANYLGLUTAMINYL DEXTRO TRYPTOPHYLPHENYLALANYL DEXTRO TRYPTOPHYLLEUCYL 11 CYCLOLEUCYLAMIDE; OCTANOYL DEXTRO ARGINYLPROLYLLYSYLPROLYL DEXTRO PHENYLALANYLGLUTAMINYL DEXTRO TRYPTOPHYLPHENYLALANYL DEXTRO TRYPTOPHYLLEUCYL 11 CYCLOLEUCYLAMIDE; SUBSTANCE P DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CANCER THERAPY; CELL STRAIN MCF 7; CHEMICAL MODIFICATION; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PEPTIDES; SUBSTANCE P; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 34548243190     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.886     Document Type: Article

References (32)

1. Nicoll RA, Schenker C, Leeman SE. Substance P as a neurotransmitter candidate. Annu. Rev. Neurosci. 1980; 3: 227-268.
2. Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boom NA, Webb DJ. Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br. J. Clin. Pharmacol. 1997; 43: 493-499.
3. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NMJ. Distinct mechanism for antidepressent activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
4. Harrison S, Geppetti P. Substance P. Int. J. Biochem. Cell Biol. 2001; 33: 555-576.
5. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance P receptors in human primary neoplasms: tumoral and vascular localization. Int. J. Cancer 1995; 61: 789-792.
6. Seckl MJ, Higgins T, Widmer F, Rozengurt E. [D-Arg1, D-Trp5,7,9, Leu 11] substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res. 1997; 57: 51-54.
7. Woll PJ, Rozengurt E. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res. 1990; 50: 3968-3973.
8. Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, Reber H, Hines OJ, Strieter R, Rozengurt E. Broad-spectrum G protein - coupled receptor antagonist, ID-Arg1, D-Trp5,7.9, Leu11] Substance P: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 2005; 65: 2738-2745.
9. Sethi T, Langdon S, Smyth J, Rozengurt E. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res. 1992; 52: 2737s-2742s.
10. Woll PJ, Rozengurt E. [D-Arg1, D-Phe5, D-Trp7,9, Leu 11]-Substance P, a potent bornbesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 1859-1863.
11. Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL. [D-Arg1, D-Phe5, D-Trp7,9, Leu 11]-substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J. Biol. Chem. 1998; 273: 3097-3104.
12. MacKinnon AC, Waters C, Jodrell D, Haslett C, Sethi T. Bombesin and substance P analogs differentially regulate G-protein coupling to the bombesin receptor. J. Biol. Chem. 2001; 276: 28083-28091.
13. Clive S, Webb DJ, MacLellan A, Young A, Byrne B, Robson L, Smyth JF, Jodrell DI. Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin. Cancer Res. 2001; 7: 3071-3078.
14. Prabhu A, Malde A, Coutinho E, Srivastava S. Solution conformation of Substance P antagonists [D-Arg1, D-Phe5, D-Trp7,9, Leu 11]-SP, [D-Arg1, D-Pro2, D-Trp7,9, Leu 11]-SP and [D-Pro2, D-Trp7,9, Leu 11]-SP by CD, NMR and MD simulations. Peptides 2005; 26: 875-885.
15. Prasad S, Rao RB, Balaram P. Contrasting solution conformation of peptide containing α,α-dialkylated amino acids with linear and cyclic side chains. Biopolymers 1995; 35: 11-20.
16. Toniolo C, Crisma M, Valle G, Bonora GM, Polinelli S, Becker EL, Freer RJ, Prasad S, Rao RB, Balaram P. Coformationally restricted formyl methionyl tripeptide chemoattractants: a three-dimensional structure-activity study of analogs incorporating a C-alpha, alpha-dialkylated glycine at position 2. Pept. Res. 1989; 2: 275-281.
17. Prasad S, Rao RB, Bergsstand H, Lindquist B, Becker EI, Balaram P. Conformation-activity correlations for chemotactic tripeptide analogs incorporating α, α-dialkylated residues with linear and cyclic side chains at position 2. Int. J. Pept. Protein Res. 1996; 48: 312-318.
18. Prasad S, Mathur A, Sharma R, Gupta N, Ahuja R, Jaggi M, Singh AT, Mukherjee R. Octapeptide analogs of somatostatin containing α, α-dialkylated amino acids with potent anticancer activity. Int. J. Pept. Res. Ther. 2006; 12: 179-185.
19. Zompra AA, Magafa V, Lamari FN, Nikolopoulou A, Nock B, Maina T, Spyroulias GA, Karamanos NK, Cordopatis P. GnRH analogs containing conformationally restricted amino acids in positions 3 and 6: differential impact on pituitary binding affinity and direct antiproliferative effect on breast cancer cells. J. Pept. Res. 2006; 66: 57-64.
20. Prasad S, Mathur A, Gupta N, Jaggi M, Singh AT, Rajendran P, Sanna V, Dutta K, Mukherjee R. Bombesin analogs containing α-aminoisobutyric acid with potent anticancer activity. J. Pept. Sci. 2007; 13: 54-62.
21. Naoto S, Guo J, Gardella TJ. Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by α-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. J. Biol. Chem. 2001; 52: 49003-49012.
22. Sagan S, Lequin O, Frank F, Convert O, Ayoub M, Lavielle S, Chassaing G. Cα methylation in molecular recognition. Application to substance P and the two neurokinin-1 receptor binding sites. Eur. J. Biochem. 2001; 268: 2997-3005.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immounol. Methods 1983; 65: 55-63.
24. Jaggi M. Mukheijee R. Development and successful transfer of human colon adenocarcinomas in vitro and in vivo models. J. Basic Appl. Biomed. 1995; 3: 27-35.
25. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003; 24: 389-427.
26. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol. 1999; 141: 1-14.
27. Mukherjee R, Burman AC, Singh AT, Jaggi M, Prasad S, Dutt S. Drug Comprising Synthetic Peptide Analogs for the Treatment of Cancer. US Patent No.7173006 B2, February 6, 2007.
28. Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT. Substance P analogs for the treatment of cancer. US Patent No.6596692 B1, July 22, 2003.
29. Prasad S, Mathur A, Jaggi M, Mukheijee R. Delivering multiple anticancer peptides as a single prodrug using lysyl - lysine as a facile linker. J. Pept. Sci. 2007; 13(7): 458-467.
30. Prasad S, Mathur A, Jaggi M, Sharma R, Gupta N, Reddy VR, Sudhakar G, Kumar SU, Kumar SK, Kunwar AC, Chakraborty TK. Furanoid sugar amino acids as dipeptide mimics in design of analogs of vasoactive intestinal peptide receptor binding inhibitor. J. Pept. Res. 2005; 66: 75-84.
31. Esteban F, Munoz M, Gonzalez-Moles MA, Rosso M. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 2006; 25: 137-145.
32. Dasgupta P, Singh A, Mukheijee R. N-terminal acylation of somatostatin analog with longchain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells. Biol. Pharm. Bull. 2002; 25: 29-36.